We are live on ! Find out more
HQL

abrdn Life Sciences Investors

55 hedge funds and large institutions have $53.3M invested in abrdn Life Sciences Investors in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

0.62% less ownership

Funds ownership: 14.53%13.91% (-0.62%)

3% less capital invested

Capital invested by funds: $54.8M → $53.3M (-$1.44M)

2% less funds holding

Funds holding: 5655 (-1)

Holders
55
Holders Change
-1
Holders Change %
-1.79%
% of All Funds
1.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
20
Reduced
16
Closed
8
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q2 2019 in Review

55 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2019, worth a combined $53.3M — down 2.6% from $54.8M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new HQL positions and 8 closed out — a net gain of 1 holder — while 20 added to existing stakes and 16 trimmed.

The largest buyer was 1832 Asset Management, opening a new position worth an estimated $1.32M. The largest seller was Raymond James & Associates, cutting an estimated $1.01M.

  • 55 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2019, down from 56 in Q1 2019.
  • Funds reported $53.3M of abrdn Life Sciences Investors stock for Q2 2019, down 2.6% quarter-over-quarter.
  • 9 funds opened new abrdn Life Sciences Investors positions in Q2 2019 and 8 closed out, a net change of +1 holder.
  • The largest abrdn Life Sciences Investors buyer in Q2 2019 was 1832 Asset Management, an estimated $1.32M added.
  • The largest abrdn Life Sciences Investors seller in Q2 2019 was Raymond James & Associates, an estimated $1.01M sold.

Based on aggregated 13F filings for Q2 2019.